|Treatments:||Chemotherapy, Hormone, Surgery||Hospital:||Technische Universität München|
This phase 2 study involved 30 male, locally advanced and high-risk prostate cancer patients with a median age of 68 years.
Patients received chemotherapy with docetaxel, androgen blockade (hormone therapy) with trimestral buserelin and bicalutamide, and surgery.
The most severe toxicities were grade 4 neutropenia and leucopenia. Grade 2 fatigue and alopecia were also reported.
The median overall survival was 85.3 months.
This study was supported by Sanofi-Aventis.
Correspondence: Dr. Mark Thalgott; email: email@example.com